CG Oncology, Inc.
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -45.74% | 5.70% | -5.75% | -20.24% | -8.35% |
| Total Depreciation and Amortization | -0.94% | 104.09% | 166.67% | 550.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.36% | 11.61% | 58.58% | -0.73% | -24.97% |
| Change in Net Operating Assets | -45.09% | -38.64% | -133.16% | 1,747.12% | -90.42% |
| Cash from Operations | -57.23% | 6.89% | -39.11% | 4.50% | -41.69% |
| Capital Expenditure | -4,242.86% | 92.78% | -592.86% | 12.50% | 92.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -343.11% | -303.45% | 2,511.47% | 100.76% | -1,780.34% |
| Cash from Investing | -343.47% | -601.86% | 969.30% | 100.75% | -1,812.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 296.77% | 83.19% | 284,636.84% | -97.21% | -99.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.51% | -114.44% | 185.71% | -35.78% | -- |
| Cash from Financing | 296.70% | 82.21% | 18,468.24% | -165.78% | -99.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.56% | -141.46% | 213.68% | 87.55% | -200.91% |